3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Small Cell Lung Carcinoma
1
Sarcoma
1
Rectal Neoplasms
1
Plasmacytoma
1
Pancreatic Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Margins of Excision
1
Homologous Recombination Deficient Solid Tumors
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Drug-Related Side Effects and Adverse Reactions
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Acrocephalosyndactylia
1
Interventions
Doxorubicin
141
Ifosfamide
85
Radiotherapy
80
Cyclophosphamide
72
Gemcitabine
63
Filgrastim
54
pembrolizumab
43
pazopanib
39
Etoposide
39
Docetaxel
39
Vincristine
37
Cisplatin
35
Trabectedin
32
Nivolumab
32
Irinotecan
26
Magnetic Resonance Spectroscopy
25
Carboplatin
25
Temozolomide
23
Ipilimumab
22
Bevacizumab
20
Radiation
19
Surgical Procedures, Operative
18
Granulocyte Colony-Stimulating Factor
18
Sirolimus
17
Mesna
17
Melphalan
17
Dactinomycin
17
Biopsy
17
eribulin
16
anlotinib
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Sarcoma
×
Drug Combinations
×
Clear all
NCT04138381
2023-03-27
SeliGIST
Grupo Espanol de Investigacion en Sarcomas
Phase 1/2
Unknown
30 enrolled